Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Citius Pharmaceuticals Inc (NQ: CTXR )

0.9456 -0.0362 (-3.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 448,020
Open 0.9765
Bid (Size) 0.9400 (18)
Ask (Size) 0.9763 (4)
Prev. Close 0.9818
Today's Range 0.9211 - 0.9765
52wk Range 0.8306 - 3.672
Shares Outstanding 145,979,429
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm
 
Via Benzinga

Performance

YTD
-43.38%
-43.38%
1 Month
+0.63%
+0.63%
3 Month
-45.97%
-45.97%
6 Month
-37.38%
-37.38%
1 Year
-73.06%
-73.06%

More News

Read More
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is Specializing in Stem Cell Therapy & Critical Cancer Care Immunotherapy
Via Get News
Exposures Product Safety
3 Reddit Stocks to Buy in May
Via InvestorPlace
Citius Pharmaceuticals (NASDAQ: CTXR) Spearheads the Global Cancer Immunotherapy Market
Via Get News
Exposures Product Safety
Citius Pharmaceuticals, Inc is helping Global Cancer Immunotherapy to reach the Market Cap of 152 Billion by 2024.
Via AB Newswire
Exposures Product Safety
Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial
Via Benzinga
The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
Via Viz Release
Exposures COVID-19 Product Safety
61 Biggest Movers From Yesterday
Via Benzinga
First Patient Dosed in Citius Pharma's Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Penny Stock Watchlist - Here Are My Five Top Picks
Via Talk Markets
FDA Signs Off Citius Pharma's Phase 2 Trial With Halo-Lido In Hemorrhoids
Via Benzinga
Citius Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
Via Benzinga
Citius Pharmaceuticals Addresses Unmet Needs for Patients with CVCs
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
Via Benzinga
Could Citius Pharmaceuticals Be a Millionaire-Maker Stock?
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
56 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
24 Stocks Moving in Friday's Pre-Market Session
Via Benzinga
58 Biggest Movers From Yesterday
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.